The Medicines Patent Pool publishes framework for prioritising target medicines for in-licensing under its newly expanded mandate
The MPP published in May a prioritisation framework that outlines a precise methodology for assessing candidate medicines that could play a major role in the MPP’s expanded mandate into new disease therapies beyond HIV, hepatitis C and tuberculosis.
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
Geneva, 20 February 2020 – The Medicines Patent Pool (MPP) today announced that it signed a sublicence agreement and partnered with Mylan, a global pharmaceutical company, to develop, manufacture and supply the first generic version of glecaprevir/pibrentasvir (G/P) – a World Health Organization (WHO)-recommended treatment for hepatitis C virus (HCV)infections.
G/P is the only all oral, once-daily pan-genotypic combination regimen recommended by WHO that is currently not available as a generic medicine. The two organisations have entered an agreement to undertake G/P manufacturing henceforth and boost the supply to make it accessible to Hepatitis C patients.
“We are pleased that, thanks to this sublicence agreement, Mylan will soon be able to increase access to the first generic version of G/P in developing countries, and supply affordable, quality-assured versions of this key treatment for treating HCV,” said Charles Gore, MPP Executive Director.
In November 2018, MPP signed a royalty-free licence a...
Geneva, 5 February 2020 - As the World Health Organization (WHO) and the global health community work to identify the best course of treatment in the fight against the novel coronavirus (2019-nCov), the Medicines Patent Pool (MPP) is ready to support access to treatment through its voluntary licensing mechanism in low- and middle- income countries.
MPP works with a wide range of treatments and holds licences for HIV antiretrovirals (ARVs) that may be effective in the treatment of 2019-nCov. MPP is currently monitoring developments closely to ensure equitable access to effective treatments. Increasing the scope of countries that a licence covers, as well as the use of ARVs for coronavirus treatment, is an opportunity for MPP to lend its model and expertise in assisting in the fight against the novel coronavirus outbreak.
Geneva, 31 January 2020 – The Medicines Patent Pool (MPP) congratulates the University of Liverpool (UoL) and the University of Washington (UoW) on receiving each a Unitaid grant to lead revolutionary long-acting medicines research.The LONGEVITY project led by the UoL aims to develop long-acting formulations for malaria and TB prevention, and a single-injection cure for hepatitis C. The GLAD project led by the UoW seeks to reduce HIV transmission and resistance to HIV drugs and improve the quality of life of those taking them through long-acting treatment regimens.
MPP is proud to partner with both projects and to use its expertise and model to address access barriers early in the development cycle and, to provide a pathway for low- and middle- income countries to promptly obtain these new products. With its recognised expertise in intellectual property-related facilitation, MPP will engage with the different stakeholders to secure partners in accelerating access to affordable quality revolutionary long-ac...
“We support the engagement of all relevant organizations, such as WHO, UNAIDS, Gavi, the Global Fund, and Unitaid and initiatives, including the recent expansion of the Medicines Patent Pool, in their work to improve access for all to safe, effective, quali...”
Unable to load twitter timeline, please allow cookie